Home / Market News / $SGRY
benzinga Corporate Catalyst Impact 55/100 ● neutral

Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target

Aug 11, 2026, 12:02 PM UTC · Primary ticker $SGRY

Cantor Fitzgerald analyst Sarah James has reiterated an 'Overweight' rating and an $18 price target for Surgery Partners (SGRY). This filing indicates continued analyst confidence in the company's prospects, which could provide some positive sentiment for investors.

Cantor Fitzgerald analyst Sarah James has reaffirmed her 'Overweight' rating and $18 price target for Surgery Partners (SGRY). This action signals that the analyst's positive outlook on the company remains unchanged, despite any recent market fluctuations or company-specific news not detailed in this filing. For investors, this reiteration can serve as a confirmation of existing bullish sentiment, potentially supporting the stock's current valuation or providing a floor against downward pressure in the short term. The long-term implications depend on whether the company's performance aligns with the analyst's expectations, but for now, it's a positive signal for SGRY shareholders. The key opportunity for traders is to consider this analyst's continued confidence as a factor in their investment decisions, potentially reinforcing a buy or hold strategy.

$SGRY positive Analyst reiterates positive rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.